Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions | Zendy

Cecilia Kållberg | Zendy; Hege Salvesen Blix | Zendy; Ramanan Laxminarayan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions

Author(s) -

Cecilia Kållberg,

Hege Salvesen Blix,

Ramanan Laxminarayan

Publication year - 2019

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.9b00076

Subject(s) - antibiotics , novelty , antibiotic resistance , intensive care medicine , norwegian , public health , medicine , biology , microbiology and biotechnology , psychology , nursing , social psychology , linguistics , philosophy

A recent analysis of antibiotics approved between 1999 and 2014, conducted by researchers at the Norwegian Institute of Public Health; the University of Oslo; the Center for Disease Dynamics, Economics & Policy (CDDEP); and Boston University, showed a lack of novelty and diversity regarding target pathogens and indications and a failure to address the most urgent resistance threats, including resistant Gram-negative bacteria. A global research and development strategy should incentivize development of broad-spectrum antibiotics for critically ill patients, as well as therapeutic alternatives to antibiotics, decreasing our dependence on traditional, small-molecule antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research